Hybio Pharmaceutical Co., Ltd.
300199
Rang in Aktien
#4739
Established in 1998 and headquartered in Shenzhen, China, Hybio Pharmaceutical... Established in 1998 and headquartered in Shenzhen, China, Hybio Pharmaceutical Co., Ltd. specializes in the global research, development, manufacturing, and commercialization of therapeutic peptide active pharmaceutical ingredients (APIs) and polypeptide medications. Its diverse product range addresses therapeutic needs such as diabetes (including liraglutide, semaglutide, and exenatide), gastrointestinal and metabolic disorders (with examples like terlipressin, desmopressin, and linaclotide), as well as applications in obstetrics and gynecology (featuring ganirelix, cetrorelix, and atosiban). Additionally, the company supplies custom peptides and provides essential working standards for peptide APIs and their impurities, offering comprehensive support for development initiatives. Beyond products, Hybio extends its expertise through Contract Research Organization (CRO) and an extensive Contract Development and Manufacturing Organization (CDMO) platform. This platform covers peptide API synthesis and purification process optimization, finished dosage form conceptualization, reference standard preparation and rigorous qualification, detailed impurity and product quality analysis, Good Manufacturing Practice (GMP) systems adhering to both EU and FDA benchmarks, and comprehensive regulatory and dossier support for both international and Chinese markets.
Aktienkurs
$3.69
Marktkapitalisierung
$3.11B
Veränderung (1 Tag)
-7.75%
Veränderung (1 Jahr)
21.56%
Land
CN
Handel Hybio Pharmaceutical Co., Ltd. (300199)
Kategorie
Healthcare
EPS für Hybio Pharmaceutical Co., Ltd. (300199)
EPS zum June 2026 TTM: $0.02
Laut den aktuellen Finanzberichten und dem Aktienkurs von Hybio Pharmaceutical Co., Ltd. beträgt das aktuelle EPS des Unternehmens (TTM) $0.02. Am Ende des Jahres 2024 betrug das EPS $-0.03 ein Rückgang im Vergleich zu dem EPS von 2023, das $-0.08 betrug.
EPS-Verlauf von Hybio Pharmaceutical Co., Ltd. von 2007 bis 2026
EPS am Ende jedes Jahres
| Jahr | EPS | ändert |
|---|---|---|
| 2026 (TTM) | $0.02 | 110.00% |
| 2025 | $0.01 | -120.80% |
| 2024 | $-0.03 | -66.54% |
| 2023 | $-0.08 | 34.48% |
| 2022 | $-0.06 | -1,207.27% |
| 2021 | $0.01 | -105.21% |
| 2020 | $-0.11 | -26.46% |
| 2019 | $-0.14 | 166.91% |
| 2018 | $-0.05 | -197.29% |
| 2017 | $0.06 | 16.42% |
| 2016 | $0.05 | -9.35% |
| 2015 | $0.05 | 70.68% |
| 2014 | $0.03 | 16.29% |
| 2013 | $0.03 | 50.00% |
| 2012 | $0.02 | 1.15% |
| 2011 | $0.02 | 30.83% |
| 2010 | $0.01 | 51.14% |
| 2009 | $0.01 | 41.94% |
| 2008 | $0.01 | 37.78% |
| 2007 | 0.00 | 0.00% |
EPS für ähnliche Unternehmen oder Wettbewerber
| Unternehmen | EPS | EPS-Differenz | Land |
|---|---|---|---|
| $6.55 | 31,077.14% |
DE
|
|
| $6.12 | 29,044.76% |
DE
|
|
| $0.72 | 3,343.33% |
JP
|
|
| $3.66 | 17,328.57% |
CH
|
|
| $0.56 | 2,549.05% |
IN
|
